Axicabtagene-ciloleucel/lisocabtagene-maraleucel/tisagenlecleucelVarious toxicities

被引：0

作者：

机构：

来源：

Reactions Weekly | 2024年 / 1999卷 / 1期

关键词：

D O I：

10.1007/s40278-024-54375-1

中图分类号：

学科分类号：

摘要：

引用

页码：66 / 66

共 50 条

[41] Axicabtagene-ciloleucel/dexamethasone/tocilizumabCytokine release syndrome, immune effector cell-associated neurotoxicity syndrome and lack of efficacy: case report
Reactions Weekly, 2023, 1940 (1) : 91 - 91
[42] Axicabtagene-ciloleucel/dexamethasone Immune effector cell-associated neurotoxicity syndrome, cytokine release syndrome and lack of efficacy: case report
Reactions Weekly, 2023, 1960 (1) : 82 - 82
[43] Axicabtagene-ciloleucel/brexucabtagene-autoleucel/tisagenlecleucelCytokine release syndrome and immune effector cell–associated neurotoxicity syndrome: 16 case reports
Reactions Weekly, 2023, 1979 (1) : 76 - 76
[44] Axicabtagene-ciloleucel/cyclophosphamide/fludarabineCytokine release syndrome, immune effector cell-associated neurotoxicity syndrome and bone marrow aplasia: case report
Reactions Weekly, 2021, 1876 (1) : 64 - 64
[45] Axicabtagene-ciloleucel/polatuzumab-vedotin/rituximabCytokine release syndrome, immune effector cell-associated neurotoxicity syndrome and lack of efficacy: case report
Reactions Weekly, 2025, 2045 (1) : 70 - 70
[46] Axicabtagene-ciloleucel/brexucabtagene-autoleucelImmune effector cell-associated cytotoxicity, cytokine release syndrome and lack of efficacy: 10 case reports
Reactions Weekly, 2023, 1984 (1) : 95 - 95
[47] Fatal late-onset CAR T-cell-mediated encephalitis after axicabtagene-ciloleucel in a patient with large B-cell lymphoma
Jung, Susanne
Greiner, Jochen
von Harsdorf, Stephanie
Popovic, Pavle
Moll, Roland
Schittenhelm, Jens
Kandilaris, Kosmas
Daniel, Volker
Kunz, Alexander
Schmitt, Michael
Dreger, Peter
BLOOD ADVANCES, 2021, 5 (19) : 3789 - 3793
[48] Axicabtagene-ciloleucel/brexucabtagene-autoleucel/tisagenlecleucelSinus bradycardia secondary to immune effector cell‐ associated neurotoxicity syndrome and cytokine release syndrome: 4 case reports
Reactions Weekly, 2022, 1924 (1) : 97 - 97
[49] Matching-Adjusted Indirect Comparison (MAIC) of Axicabtagene Ciloleucel (Axi-Cel) and Lisocabtagene Maraleucel (Liso-Cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) After Two or More Prior Lines of Therapy
Oluwole, Olalekan O.
Chen, Jenny M. H.
Chan, Keith
Patel, Anik R.
Jansen, Jeroen P.
Keeping, Sam
Bashir, Zahid
Zheng, Yan
Snider, Julia
Locke, Frederick L.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S388 - S388
[50] A Multicenter Retrospective Analysis of Outcomes and Toxicities with Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas
Riedell, Peter A.
Walling, Chase
Nastoupil, Loretta J.
Pennisi, Martina
Maziarz, Richard T.
McGuirk, Joseph P.
Oluwole, Olalekan O.
Bachanova, Veronika
Hwang, Wei-Ting
Schuster, Stephen J.
Perales, Miguel
Bishop, Michael R.
Porter, David L.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S41 - S42

← 1 2 3 4 5 →